# Program 02: Gynecologic Cancers

> **NIH NIH P30** · DANA-FARBER CANCER INST · 2024 · $40,515

## Abstract

Gynecologic Cancers Program
Project Summary / Abstract
The mission of the Gynecologic (Gyn) Cancers Program is to improve patient outcomes by developing novel
strategies for early detection, therapy, and prevention through integrated translational research across the
consortium. A related mission is to train and educate the next generation of translational researchers, clinical
trialists, outcomes researchers, and basic scientists who focus on Gyn cancers. The Program encompasses
investigation of all Gyn cancers including ovarian, endometrial, cervical, vaginal, vulvar, and germ cell cancers
as well as gestational trophoblastic disease. Moreover, we respond to the increasing incidence of endometrial
cancer (EnCa) in our catchment area (Massachusetts) as well as racial disparities in diagnosis and treatment
of cervical cancer and EnCa in Massachusetts.
A previous DF/HCC Program in Gyn Cancers was not included in the last CCSG renewal (2016); the current
Program is thoroughly revamped. Its 59 members (47 primary and 12 secondary) represent five DF/HCC
institutions and 6 academic departments. In 2019, peer-reviewed grant funding attributed to the Program was
$2.1 million in direct costs from the NCI and $1.2 million from other sponsors. During the current funding
period, primary Program members published 629 cancer-relevant papers. Of these, 20% were inter-
institutional, 27% were intra-programmatic, and 34% were inter-programmatic collaborations between two or
more DF/HCC members.
For the next CCSG funding period, the Program’s Specific Aims are to: 1) Develop and implement early
detection, prevention, diagnostic, and prognostic methods for Gyn cancers in Massachusetts and across
the US; 2) Develop and advance novel therapeutic strategies for Gyn cancers; and 3) Educate and mentor
the next generation of leaders for Gyn Cancers through fellowship programs, junior faculty development, and
placement of junior faculty on national committees. These goals align perfectly with the DF/HCC strategic plan
and will require the full suite of CCSG components: shared resources, collaborative infrastructure, an effective
system for clinical trial review and conduct, and structured processes for community engagement and cancer
research training.

## Key facts

- **NIH application ID:** 10768698
- **Project number:** 5P30CA006516-59
- **Recipient organization:** DANA-FARBER CANCER INST
- **Principal Investigator:** URSULA Anne MATULONIS
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $40,515
- **Award type:** 5
- **Project period:** 1997-03-10 → 2026-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10768698

## Citation

> US National Institutes of Health, RePORTER application 10768698, Program 02: Gynecologic Cancers (5P30CA006516-59). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10768698. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*